Studie zur ambulanten moderaten Ganzkörperhyperthermie bei Fibromyalgiesyndrom

Zusammenfassung

Die Genese des Fibromyalgiesyndroms (FMS) ist immer noch unklar und stellt für Behandelnde und medizinisches Fachpersonal ein Rätsel dar. Generalisierte Schmerzen unterschiedlicher Lokalisationen sowie damit einhergehende Begleitsymptome wie Fatigue, Schlafstörungen, vegetative und psychische Störungen sind führend und bedürfen einer komplexen Behandlung. Am Krankenhaus für Naturheilwesen (KfN) in München sind FMS-Patienten in eine naturheilkundliche Komplexbehandlung eingebunden und werden effektiv und erfolgreich mit serieller moderater Ganzkörperhyperthermie (mGKHT) behandelt. Da die Studienlage dazu noch recht dünn ist und in keiner der Studien die Effektivität der mGKHT als Monotherapie in der Behandlung der FMS untersucht wurde, soll dies in einer eigenen Studie, beginnend 2022, ermittelt werden. Der Beitrag geht auf die Studienlage ein und zeigt das Studiendesign der prospektiven Studie.

Abstract

The genesis of the fibromyalgia syndrome (FMS) is still unclear and poses a mystery to practitioners and medical staff. Generalized pain of different localizations as well as accompanying symptoms such as fatigue, sleep disorders, vegetative and psychological disorders are predominant and require a complex treatment. At the Krankenhaus für Naturheilwesen (KfN) (Clinic for Internal Medicine, Naturopathy and Homeopathy) in Munich, FMS patients are included in a naturopathic complex treatment and are effectively and successfully treated with serial moderate whole-body hyperthermia (mGKHT). Since the study situation on this treatment is still quite thin and none of the studies has investigated the efficacy of mGKHT as a monotherapy in the treatment of FMS, this will be determined in a separate study starting in 2022. The article reviews the study situation and shows the study design of the prospective study.

Schlüsselwörter

Fibromyalgiesyndrom - ambulante moderate Ganzkörperhyperthermie - Infrarot-A-Strahlung

Keywords

Fibromyalgia syndrome - outpatient moderate whole-body hyperthermia - infrared A radiation

Publication History

Article published online:
21 June 2022

• Literatur

• 1 Wolfe F. The history of the idea of widespread pain and its relation to fibromyalgia. Scand J Pain 2020; 20 (04) 647-650
• 2 Inanici F, Yunus MB. History of fibromyalgia: Past to present. Curr Pain Head Rep 2004; 8: 369-378
• 3 Winkelmann A, Wetzel S, Benischek J. et al. Das Fibromyalgiesyndrom – FMS. manuelletherapie 2019; 23: 3
• 4 Deutsche Fibromyalgie Vereinigung (DFV) e. V.. Im Internet: Accessed May 02, 2022 at: http://www.fibromyalgie-fms.de
• 5 Marques AP, Santo ASDE, Berssaneti AA. et al. Prevalence of fibromyalgia: Literature review update. Rev Bras Reumatol Engl 2017; 57 (04) 356-363
• 6 Wolfe F, Brähler E, Hinz A. et al. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: Results from a survey of the general population. Arthritis Care Res 2013; 65 (05) 777-785
• 7 Wolfe F, Ross K, Anderson J. et al. Aspects of fibromyalgia in the general population: Sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 1995; 22: 151-156
• 8 Brockow T, Wagner A, Franke A. et al. Randomisierte, kontrollierte Studie zur Wirksamkeit und Verträglichkeit einer milden wassergefilterten Infrarot-A-Ganzkörperhyperthermie als Zusatzbehandlung zu einer multimodalen rehabilitativen Standardtherapie bei der Behandlung der Fibromyalgie. Phys Med Rehab Kuror 2008; 18: 4
• 9 Winkelmann A, Perrot S, Schaefer C. et al. Impact of fibromyalgia severity on health economic costs. Appl Health Econ Health Policy 2011; 9: 125-136
• 10 Walitt B, Nahin RL, Katz RS. et al. The prevalence and characteristics of fibromyalgia in the 2012 National Health Interview Survey. PLoS One 2015; 10: e0138024
• 11 AWMF. Deutsche Schmerzgesellschaft e. V.. 2017 Im Internet: Accessed November 21, 2020 at: https://www.awmf.org/leitlinien/aktuelle-leitlinien/ll-liste/deutsche-gesellschaft-zum-studium-des-schmerzes-dgss.html
• 12 Häuser W, Ablin J, Fitzcharles MA. et al. Fibromyalgia. Nat Rev Dis Primers 2015; 1: 15022
• 13 Eich W. Definition, Klassifikation, klinische Diagnose und Prognose des Fibromyalgiesyndroms. Schmerz 2017; 4: 231-238
• 14 Wolfe F, Smythe HA, Yunus MB. et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthr Rheum 1990; 33: 160-172
• 15 Wolfe F, Clauw DJ, Fitzcharles MA. et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: A modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011; 38: 1113-1122
• 16 Wolfe F, Clauw DJ, Fitzcharles MA. et al. Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Sem Arthr Rheum 2016; 46 (03) 319-329
• 17 Häuser W, Jung E, Erbslöh-Möller B. et al. Validation of the Fibromyalgia Survey Questionnaire within a cross-sectional survey. PLoS One 2012; 7: e37504
• 18 Häuser W, Schild S, Kosseva M. et al. Validierung der deutschen Version der regionalen Schmerzskala zur Diagnose des Fibromyalgiesyndroms. Schmerz 2010; 24: 226-235
• 19 Arnold LM. AAPT Diagnostic criteria for fibromyalgia. Am Pain Soc 2019; 20: 6
• 20 Salaffi F, Sarzi-Puttini P, Girolimetti R. et al. Development and validation of the self-administered fibromyalgia assessment status: A disease-specific composite measure for evaluating treatment effect. Arthr Res Ther 2009; 11 (04) R125
• 21 Kang JH, Choi SE, Xu H. et al. Comparison of the AAPT fibromyalgia diagnostic criteria and modified FAS criteria with existing ACR criteria for fibromyalgia in Korean patients. Rheum Ther 2021; 8: 1003-1014
• 22 Salaffi F, DiCarlo M, Farah S. et al. Diagnosis of fibromyalgia: Comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified fibromyalgia assessment status. Rheumatology (Ox) 2020; 59 (10) 3042-3049
• 23 Petzke F, Brückle W, Eidmann U. et al. Allgemeine Behandlungsgrundsätze, Versorgungskoordination und Patientenschulung beim Fibromyalgiesyndrom. Schmerz 2017; 31: 246-254
• 24 Üçeyler N, Burgmer M, Friedel E. et al. Ätiologie und Pathophysiologie des Fibromyalgiesyndroms. Schmerz 2017; 31: 236-245
• 25 Cagnie B, Coppieters I, Denecker S. et al. Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. Semin Arthr Rheum 2014; 44 (01) 68-75
• 26 Dehghan M, Schmidt-Wilcke T, Pfleiderer B. et al. Coordinate-based (ALE) meta-analysis of brain activation in patients with fibromyalgia. Hum Brain Mapp 2016; 37 (05) 1749-1758
• 27 Aoki Y, Inokuchi R, Suwa H. Reduced N-acetylaspartate in the hippocampus in patients with fibromyalgia: A meta-analysis. Psych Res Neuroimag 2013; 213 (03) 242-248
• 28 Martínez-Martínez LA, Mora T, Vargas A. et al. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome and interstitial cystitis: A review of case control studies. J Clin Rheumatol 2014; 20: 146-150
• 29 Leinders M, Doppler K, Klein T. et al. Increased cutaneous miR-let-7d expression correlates with small nerve fiber pathology in patients with fibromyalgia syndrome. Pain 2016; 157 (11) 2493-2503
• 30 Oaklander AL, Herzog ZD, Downs HM. et al. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain 2013; 154 (11) 2310-2316
• 31 Üçeyler N, Zeller D, Kahn AK. et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain 2013; 136 (06) 1857-1867
• 32 Lee YC, Lu B, Boire G. et al. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Ann Rheum Dis 2013; 72: 949-954
• 33 Sommer C, Häuser W, Gerhold K. et al. Etiology and pathophysiology of fibromyalgia syndrome and chronic widespread pain. Schmerz 2008; 22 (03) 267-282
• 34 Hsiao MY, Hung CY, Chang KV. et al. Is serum hypovitaminosis d associated with chronic widespread pain including fibromyalgia? A meta-analysis of observational studies. Pain Phys 2015; 18 (05) E877-E887
• 35 Afari N, Ahumada SM, Wright LJ. et al. Psychological trauma and functional somatic syndromes: A systematic review and meta-analysis. Psychosom Med 2014; 76 (01) 2-11
• 36 Chang MH, Hsu JW, Huang KL. et al. Bidirectional association between depression and fibromyalgia syndrome: A nationwide longitudinal study. J Pain 2015; 16 (09) 895-902
• 37 Cassisi G, Sarzi-Puttini P, Cazzola M. Chronic widespread pain and fibromyalgia: Could there be some relationships with infections and vaccinations?. Clin Exp Rheumatol 2011; 29 (06) 118-126
• 38 Wolfe F, Häuser W, Walitt BT. et al. Fibromyalgia and physical trauma: The concepts we invent. J Rheumatol 2014; 41 (09) 1737-1745
• 39 Sommer C, Häuser W, Burgmer M. et al. Etiology and pathophysiology of fibromyalgia syndrome. Schmerz 2012; 26 (03) 259-267
• 40 Hackshaw KV. The search for biomarkers in fibromyalgia. Diagnostics 2021; 11 (02) 156
• 41 Schmidt K. Hyperthermie und Fieber. Stuttgart: Hippokrates; 1987
• 42 Heckel M. Ganzkörperhyperthermie und Fiebertherapie – Grundlagen und Praxis. Stuttgart: Hippokrates; 1990
• 43 Vaupel P, Stofft E. Wassergefilterte Infrarot-A-Strahlung im Vergleich zu konventioneller Infrarotstrahlung oder Fango-Paraffin-Packungen: Temperaturprofile bei lokaler Wärmetherapie. In: Krüger W, Vaupel P. Hrsg. Wärmetherapie mit wassergefilterter Infrarot-A-Strahlung. Stuttgart: Hippokrates; 1995: 135-147
• 44 Kobayashi Y, Ito Y, Ostapenko VV. et al. Fever-range whole-body heat treatment stimulates antigen-specific T-cell responses in humans. Immunol Letters 2014; 162: 256-261
• 45 Mace TA, Zhong L, Kokolus KM. et al. Effector CD8 + T cell IFN-γ production and cytotoxicity are enhanced by mild hyperthermia. Int J Hyperthermia 2012; 1: 9-18
• 46 Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs 2009; 6: 550-558
• 47 Bakhshandeh-Bath A, Stoltz AS, Homann N. et al. Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma. Anticancer Res 2009; 8: 3069-3077
• 48 Lange U, Müller-Ladner U, Dischereit G. Wirkung iterativer Ganzkörperhyperthermie mit wassergefilterter Infrarot-A-Strahlung bei ankylosierender Spondylitis – eine kontrollierte, randomisierte, prospektive Studie. Akt Rheumatol 2017; 2: 122-128
• 49 Zauner D, Quehenberger F, Hermann J. et al. Whole body hyperthermia treatment increases interleukin 10 and toll-like receptor 4 expression in patients with ankylosing spondylitis: A pilot study. Int J Hyperthermia 2014; 6: 393-401
• 50 Lange U, Schwab F, Müller-Ladner U. et al. Wirkung iterativer Ganzkörperhyperthermie mit wassergefilterter Infrarot-A-Strahlung bei Arthritis psoriatica – eine kontrollierte, randomisierte, prospektive Studie. Akt Rheumatol 2014; 5: 310-316
• 51 Förster J, Fleischanderl S, Wittstock S. et al. Letter to the editor: Infrared-mediated hyperthermia is effective in the treatment of scleroderma-associated Raynaud’s phenomenon. J Investig Dermatol 2005; 6: 1313-1316
• 52 Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: The immune system feels the heat. Nat Rev Immunol 2015; 6: 335-349
• 53 Ettrich U, Konrad B, Prate K. et al. Milde Ganzkörperhyperthermie in Kombination mit stationärer multimodal orientierter Schmerztherapie – Evaluation bei Patienten mit chronischem unspezifischem lumbalem Rückenschmerz. Orthopäde 2014; 2: 165-174
• 54 Stange R. Wassergefilterte Infrarot-Hyperthermie – Lassen sich muskuloskelettale Schmerzen wegschmelzen?. zkm 2017; 3: 52-55
• 55 Lampert H. Heilung durch Überwärmung. Hannover: Bruno Wilkens; 1967
• 56 Reichel M, Scheeren T, Douwes O. et al. Tief intravenöse Analgosedierung zur extremen Ganzkörperhyperthermie in Kombination mit Chemotherapie. Naturheilkunde 2004; 3: 4-8
• 57 Hegewisch-Becker S, Gruber Y, Corovic A. et al. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: A phase II study. Ann Oncol 2002; 8: 1197-1204
• 58 Schleenbecker HG, Schmidt KL. Zur Wirkung einer iterativen milden Ganzkörperhyperthermie auf den Fibromyalgieschmerz – Pilotstudie. Phys Med Rehamed Kurmed 1998; 8 (04) 113-117
• 59 Walz J. Ganzkörperhyperthermie in der Schmerztherapie. Schmerz 2013; 27: 38-45
• 60 Romeyke T. Multi-model pain therapy of fibromyalgia syndrome with integration of systemic whole-body hyperthermia – effects on pain intensity and mental state: A non-randomised controlled study. J Musculoscel Pain 2014; 22 (04) 341-355
• 61 Romeyke T, Scheuer HC, Stummer H. Fibromyalgia with severe forms of progression in a multidisciplinary therapy setting with emphasis on hyperthermia therapy – a prospective controlled study. Clin Interv Aging 2015; 10: 69-79
• 62 Raffaeli W. Identification of MOR-positive B cell as possible innovative biomarker (Mu lympho-marker) for chronic pain diagnosis in patients with fibromyalgia and osteoarthritis diseases. Int J Molecul Sci 2020; 21: 1499
• 63 Hackshaw KV. Correction: Metabolic fingerprinting for diagnosis of fibromyalgia and other rheumatologic disorders. J Biol Chem 2020; 295 (17) 5834